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Abstract 
 
Auto immune hepatitis is associated with characteristic autoantibodies and hypergammaglobulinemia. The aim of 
study is to see prevalence of various types of AIH. Material: Study included 66 cases of AIH, 16 cases of chronic 
viral hepatitis [8 hepatitis B, 8 hepatitis C] and 18 healthy control between a period of 1.5 years. Antinuclear 
antibody [ANA], anti-mitochondrial antibody [AMA], anti smooth muscle antibody [ASMA], anti F-actin antibody, 
anti parietal cell antibody were done by indirect fluorescent method [IIF] on frozen section of rat liver, stomach, and 
kidney. It was also done by immunodot method. ANA was repeated by ELISA technique.Result:AIH-1 formed 
maximum cases [89.39%] followed by AIH-2 [9.09%] and AIH-3 [1.51%]. In AIH-1 23.7% and in AIH-2 66.66% 
were children. Male predominance was in AIH-1 [59.3%].Weakness, loss of appetite, weight loss and jaundice were 
common in more than 86% patients in all types of AIH. Ascitis was more common in AIH-1 [61%] than in AIH-2 
[33.3%]. ASMA antibody was positive in all cases of AIH-1 while anti LKM was positive in AIH-2. ANA was 
positive in 16.9% cases of AIH by IFT method and 30.54% by ELISA. APCA was positive in 27% cases. Two cases 
each of AIH-1 were positive for AMA, endomysium, anticentromere, anti Smith, anti RNP and anti-laminin 
antibody. All AIH-1 and AIH-2 cases had significantly elevated transaminases, bilirubin, alkaline phosphatase and 
serum IgG.Thus, our study concludes that AIH1 is more common than AIH2 and ASMA is more common antibody. 
Key Words: Autoimmune hepatitis, autoimmune liver disease, chronic hepatitis, anti smooth muscle antibody, anti 
Factin antibody, anti LKM antibody, anti soluble liver antigen antibody. 
Introduction 
Autoimmune hepatitis is a chronic disease 
characterized by interface hepatitis 
hypergammaglobulinemia and autoantibodies[1, 2]. 
Like other autoimmune diseases its pathogenesis is not 
clear. 
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It is both due to genetic [mostly HLA related] and 
environmental factor[3] and impaired T cell function. It 
was first described in 1950 by Waldenstrom[4] in 
young female who presented with chronic hepatitis, 
jaundice, elevated serum immunoglobulins and 
amenorrhoea[5]. Kunkel et al in 1951 confirmed 
Waldenstrom observation and described additional 
extra hepatic manifestations of fever and arthritis. In 
1954 Italian physician Leoni[6] reported lupus 
erythematous cells [LE cells] in the asitic fluid of 
patient with cirrhosis and one year later Josbe and 
King[7] in 1955 from Melbourne Australia described 
LE cells in blood of two patients who had chronic 
hepatitis with hypergammaglobulinemia.  
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In 1956 MacKaye et al[8] reported 6 additional cases 
of chronic active hepatitis with hypergamma-
globulinemia and LE cells. In view of LE cells they 
proposed the term of lupoid hepatitis. 
AIH is serologically heterogenous disease. Based on 
the nature of autoantibodies it is classified into 2 major 
types – type 1 AIH[9] which shows for positivity for 
antinuclear antibody [ANA] and anti smooth muscle 
antibody[SMA] and type 2 AIH[10] which shows 
positivity for anti-liver kidney microsomal type 1 [anti 
LKM- 1] or anti liver cytosol type 1 antibody [anti LC-
1] [11, 12, 3]. 
Antibody to soluble liver antigen [SLA] also called 
liver pancreas antigen[LP] was identified in 1987 by 
Mann et al., [13] . It is less frequent but specific 
diagnostic marker of AIH and carries poor prognosis, 
short survival and 3 fold increased risk of death and 
more relapse [14, 15, 16]. It was kept in AIH 3 by 
some worker but later was considered in AIH 1 [17]. 
Most of the liver specific autoantibodies are detected 
by Indirect Immunofluorescent Test [IIF] on combined 
frozen sections of liver, kidney and stomach of rodent 
where serum is diluted in more than 1:40 for adult and 
1:20 for children. 
In IIF, anti SMA is detected in smooth muscle of 
arterial wall of all 3 substrate  [SMA-V pattern], in 
mesangium of kidney [SMA-G pattern], gastric 
muscularis externa, muscularis mucosa, and smooth 
muscle fibre that extend from muscularis mucosa to 
lamina propria. Factin smooth muscle antibody binds 
to contractile fibres around tubules [SMA-T] giving 
rise to picket fence appearance which frequently stains 
mesangial cells of glomeruli. SMA VGT pattern was 
described by Bottazzoet al., 1976[18]. Out of this 
SMA-V pattern is not specific because this staining can 
be due to antibody to vimentin intermediate filaments 
which can be seen in many viral infections. ELISA for 
Factin may give rise to false positive result specifically 
when SMA is present but not with SMA T[17]. 
Autoantibody to liver microsome antibody is found in 
type 2 AIH. It is directed against cytocthrome 
P4502D6 [Cyp2D6] [19, 20]. It gives staining to 
proximal renal tubules and hepatocytes cytoplasm [11, 
16] but 10% of patients of Hepatitis C also have anti 
LKM-1 antibody. 
Antibodies of LC-1 whose target antigens for a 
immunotransferasecyclodeaminase, 67 kD cytosolic 
proteins [21] found in 30% with LKM-1 positive AIH 
2 and in 10% it is only autoantibody of AIH 2. Anti 
LC-1 stains hepatocytes cytoplasm but spares 
hepatocytes around central vein. Its presence is 
associated with poor clinical course and more rapid 
progression. [23]. 
ANA is another autoantibody found in AIH. It 
may be directed against ribonucleotide protein 
complex[24]. Homogenous pattern is more typical 
[25]. In 55-60% cases both ANA and SMA may 
coexist together [24]. Besides this antibody to 
asialoproteins receptors [ASGPR], perinuclear anti 
neutrophil cytoplasmic antibody [pANCA] [26], 
antibody to histone, ds DNA [27], chromatin [28] and 
anti mitochondrial antibody [anti M2] [29] may also be 
found in AIH. 
AIH is very common in our area but very few studies 
have been done in India. Aim of present study is to find 
clinical, biochemical, and autoantibody profile of AIH 
and its comparison with healthy controls and chronic 
viral hepatitis. 
Materials and Methods 
Present study was conducted in UGC Advanced 
Immunodiagnostic Training and Research Centre of 
Institute of Medical Sciences, Banaras Hindu 
University. Clinical details and sample were taken 
from patients between January 2016 to August 2017. 
This included 66 patients of AIH, 16 patients of 
chronic viral hepatitis and 18 healthy controls. 
Diagnosis of AIH was done by International AIH 
criteria as described by Alvasezet al., 1999 [30]. 
In all patients after consent 3ml blood was taken in 
plain vial for serum bilirubin, aminotransferases, 
alkaline phosphatase, another 4 ml blood was taken in 
plain vial for autoantibody. Serum after separation was 
stored in -200C deep freezer till test was performed. 
Anti smooth muscle antibody [ASMA] anti Factin 
antibody, anti LKM antibody, ANA, antimitochondrial 
antibody, anti parietalcell antibody, anti laminin 
antibody was detected by indirect fluorescent test on 
combined frozen section of rat liver, kidney and 
stomach. In children serum was diluted in 1:20 dilution 
and in adult it was diluted in 1:40 dilution initially. 
In all cases test was repeated by immunodot method. 
The kit was of D- tek company supplied by Anand 
Brother. Kit of immunofluorescent of Bioscientifica 
company of Argentina was used. This was supplied by 
Pamed services Pvt Limited.   
Results 
Study included 66 patients of AIH, out of which 59 
cases [84.4%] were of type 1 AIH, 6 cases of type 2 
AIH, [9.09%] who had anti LKM antibody, and only 
one case had type 3 AIH [1.51%] – positive for anti 
SLA antibody. Besides this 16 cases of chronic viral 
Hepatitis [8 cases were hepatitis B positive and 8 cases 
were hepatitis C positive] and 18 cases of healthy 
controls for comparison, were also taken. 
Age wise distribution showed that 1/3rd cases [32.2%] 
of AIH 1 were between 21 -30 years, 22% were 
between 31-40 years of age and 22% were above 40 
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years of age [41-55 years]. In AIH type 2 66.66% were 
children below 16 years of age, out of this 33.33% 
children were below 10 years of age. Rest 33.33% 
patients were young adults between 21-40 years of age. 
In type 3 AIH only one patient was 10 years old female 
child. 
Contray to this in chronic viral hepatitis 31.2% were 
between 21-30 years, 25% were between 31-50 years 
of age, 31.2% were above 50 years of age, and 12.4% 
patients were children below 16 years [Table 1] 
Table 1: Showing age wise distribution of various patients of chronic hepatitis 
Age in 
years 
 
Type 1 AIH 
n = 59 
Type 2 AIH 
n = 6 
Type 3 AIH 
n = 1 
Chronic viral 
hepatitis 
n = 16 
No. % No. % No. % No. % 
 0-10.9 1 1.7 2 33.33 1 100 1 6.2 
11-20.9 13 22.0 2 33.33 0 0 1 6.2 
21-30 19 32.2 1 16.7 0 0 5 31.2 
31-40 13 22.0 1 16.7 0 0 2 12.5 
41-50 6 10.2 0 0 0 0 2 12.5 
>50 7 11.9 0 0 0 0 5 31.2 
Sex wise distribution showed that in AIH males were predominantly affected [59.3%] whereas in AIH 2 
both males and females were equally affected while in AIH 3 only one female patient was found [Table 2] 
Table 2: Showing sex wise distribution of various types of chronic hepatitis 
Sex of the patient AIH 1 AIH 2 AIH 3 Chronic Viral 
hepatitis 
No. % No. % No. % No. % 
Females 24  3 50 1 100 8 50 
Males 35  3 50 0 0 8 50 
Total Cases 9  6  0 0 16  
Male : Female ratio 1.5:1  1:1    1:1  
 
Analysis of clinical features showed that weakness 
[93.2%], loss of appetite [86.4%], pallor [84.7%], 
weight loss [81.4%], icterus [72.9%] were more 
common in AIH 1.Ascitis [61.1%] and pain in 
abdomen [69.5%] were also seen. 
One patient of AIH 3 had weakness, weight loss, loss 
of appetite, pain in abdomen and pallor. 
In type 2 AIH weakness [100%], loss of appetite 
[86.4%], pallor [100%] were more commonly seen. 
Jaundice was present in 66.66% cases while ascites 
was present in 33.33% cases. 
Contrary to this patients of chronic viral hepatitis were 
mostly asymptomatic, above described features were 
present in only 18.7% cases. [Table 3] 
Table 3: Showing clinical features of AIH 
Clinical Features AIH 1[59] AIH 2[6] AIH 3[1] Viral Hepatitis[16] 
Diarrhoea 10 16.9 0 0 0 0 0 0 
Weakness 55 93.2 6 100 1 100 3 18.7 
Weight Loss 48 81.4 2 33.33 1 100 3 18.7 
Loss of Appetite 51 86.4 5 83.3 1 100 3 18.7 
Pain abdomen 41 69.5 2 33.33 1 100 3 18.7 
Pallor 50 84.7 6 100 1 100 3 18.7 
Icterus 43 72.9 4 66.66 0 0 3 18.7 
Ascitis 36 61.0 2 33.33 0 0 1 6.2 
 
Among the autoantibody profile most common 
autoantibody detected was anti smooth muscle 
antibody [ASMA-76.3%] followed by Factin antibody 
[50.8%], antinuclear antibody [ANA-30.54%] and anti 
parietalcell antibody [APCA-27.11%]. Besides this anti 
centromere antibody, anti Smith [Sm] antibody, anti 
ribonucleoprotein antibody [anti RNP], anti nuclear 
laminin antibody and anti endomysium antibody were 
detected in small number of cases [3.41% each] 
[Table4] [Figure 1,2,3,4,5,6,7] 
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Figure 1: Case of AIH type 1, positive for anti 
smooth muscle antibody, wall of blood vessel, 
muscularis propria of stomach wall are showing 
fluorescence of ASMA. On the left side F-actin 
fibres in the parietal layer of stomach due to F-
actin Ab is also found. [IIF×400]. 
Figure 2: Case of AIH type 1 showing F-actin Ab 
positivity, thread like F-actin in the parietal layer 
of stomach showing fluorescence. [IIF×400] 
  
  
Figure 3: Case of type 1 AIH showing ANA 
positivity. Nuclei of liver cells show diffuse 
fluorescence & some nuclei showing nucleolar & 
speckled pattern. [IIF×400] 
Figure 4: Type 2 AIH showing LKM Ab positivity. 
Diffuse fluorescence of proximal tubular epithelial 
cells is seen. [IIF×400] 
  
Figure 5: AMA positive case showing diffuse small 
multiple dot like fluorescence in cytoplasm of 
hepatocyte. [IIF×400] 
Figure 6: Case of AIH type 1 showing anti parietal 
cell Ab positivity. The parietal cell of stomach 
showing strong fluorescence. There is no 
fluorescence on hepatocyte cytoplasm & renal 
tubular epithelium. [IIF×100] 
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Figure 7: AIH type 1 showing predominantly peripheral staining of nuclei of hepatocyte, some cells show 
diffuse pattern also. This case was positive of ANA along with anti laminin Ab. This case was anti dsDNA 
Ab negative. [IIF×400] 
 
Table 4: Frequency of various autoantibodies in different types of hepatitis 
Autoantibodies 
 
AIH 1 
n=59 
AIH 2 
n=6 
AIH 3 
n=1 
Viral Hepatitis 
n=16 
Control[12] 
No % No % No % No % No % 
ASMA 45 76.3 2 33.33 0 0 2 
 
125 
Weakly 
positive 
2 
 
16.6 
Weakly 
positive 
Factin 30 50.8 1 16.6 0 0 1 6.2 0 0 
IIF method 
ANA 
ELISA 
10 
 
18 
16.9 
 
30.54 
1 
 
1 
16.6 
 
16.6 
0 
 
1 
0 
 
100 
0 
 
0 
0 
 
0 
0 
 
0 
0 
 
0 
LKM 0 0 6 100 0 0 0 0 0 0 
AMA 2 3.4 0 0 0 0 0 0 0 0 
APCA 16 27.1 0 0 0 0 0 0 0 0 
EMA 2 3.4 0 0 0 0 0 0 0 0 
SLA 0 0 0 0 0 0 0 0 0 0 
Anticentromere 2 3.38 0 0 0 0 0 0 0 0 
Anti Smith + anti  
RNP antibody 
2 3.38 0 0 0 0 0 0 0 0 
Anti Laminin 
antibody 
2 3.38 0 0 0 0 0 0 0 0 
 
Serum SGOT and SGPT were significantly elevated in 
AIH 1, AIH 3 and hepatitis B and hepatitis C as 
compared to controls. One case of AIH 3 also had 
raised SGOT, SGPT. Intra group comparison showed 
no significant difference between AIH 1 vs AIH 2, 
AIH 1 vs Hepatitis C. Only SGOT was significantly 
more in AIH 1 as compared to hepatitis B. [Table 5 and 
6] 
Total serum bilirubin, direct bilirubin, indirect bilirubin 
and alkaline phosphatase were significantly elevated in 
AIH 1, AIH 2 and AIH 3 as compared to control. In 
hepatitis B patients only alkaline phosphatase was 
significantly elevated as compared to controls while 
bilirubin rise was not significant. Contrary to hepatitis 
B, in hepatitis C all total bilirubin, direct bilirubin, 
indirect bilirubin and alkaline phosphatase was 
significantly more as compared to control [Table 6 and 
7] 
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Table 5: Showing serum SGOT, SGPT in different type of hepatitis 
Groups No of Cases SGOT [U/ml] 
Mean ± SD 
SGPT [U/ml] 
Mean ± SD 
Healthy contacts 18 6.778 ± 4.7719 11.000 ± 7.3324 
AIH 1 59 176.522 ± 424.857 156.802 ± 237.03 
AIH 2 6 1057.333 ± 2210.67 330.333 ± 426.08 
AIH 3 1 269.000 223.000 
Hepatitis B 8 40.646.59 85.188115.89 
Hepatitis C 8 70.50071.51 73.25036.38 
Table 6: Showing statistical analysis at SGOT /SGPT in AIH vs control 
Groups SGOT SGPT 
Healthy control vs AIH 1 Z=6.313 
P=0.000 
Z=5.313 
P=0.000 
Control vs AIH 2 Z=3.701 
P=0.000 
Z=3.546 
P=0.000 
Control vs Hepatitis B Z=2.954 
P=0.003 
Z=2.986 
P=0.003 
Control vs Hepatitis C Z=4.060 
P=0.000 
Z=3.900 
P=0.000 
AIH 1 vs AIH 2 Z=1.247 
P=0.213 
Z=1.167 
P=0.243 
AIH 1 VS Hepatitis B Z=2.553 
P=0.011 
Z=1.354 
P= 0.176 
AIH 1 vs Hepatitis C Z=1.189 
P=0.234 
Z=0.184 
P= 0.854 
Table 7: Showing total bilirubin, direct bilirubin, indirect bilirubin and alkaline phosphatase in different 
types of hepatitis 
Group No of 
cases 
Total Bilirubin 
Mean± SD 
Direct Bilirubin 
Mean ± SD 
Indirect 
Bilirubin 
Mean ± SD 
Alkaline 
Phosphatase 
Mean ±SD 
Controls 18 0.422 ± 0.10033 0.2333 ± 0.09701 0.1889 ± 0.8324 100.44 ± 32.522 
AIH 1 59 5.0958 ± 7.4580 3.2268 ± 5.5935 1.8708 ± 2.46741 244.17 ±174.390 
AIH 2 6 7.7000 ± 6.78999 4.666 ± 5.0630 3.0333 ± 2.0539 319.17 ± 215.511 
AIH 3 1 1.200 .400 0.800 268.00 
Hepatitis B 8 0.8500 ± 0.89921 0.5125 ± 0.73764 0.3375 ± 0.25600 170.13 ± 89.788 
Hepatitis C 8 4.0500 ± 8.99413 2.4250 ± 5.3293 1.6125 ± 3.67246 245.13 ± 76.48 
Table 8: Showing statistical significance of various bilirubin and alkaline phosphatase in various groups 
Groups Direct 
Bilirubin 
Indirect 
Bilirubin 
Total Bilirubin Alkaline 
phosphatase 
Healthy Controls vs AIH 1 Z=5.312 
P=0.000 
Z=4.565 
P=0.000 
Z=5.280 
P=0.000 
Z=4.267 
P=0.000 
Controls vs AIH 2 Z=3.700 
P=0.000 
Z=2.953 
P=0.003 
Z=3.695 
P=0.000 
Z=2.236 
P=0.025 
Healthy Control vs Hepatitis B Z=1.206 
P=0.228 
Z=0.406 
P=0.685 
Z=1.024 
P=0.306 
Z=2.281 
P=0.023 
Control vs Hepatitis C Z=4.033 
P=0.000 
Z=3.292 
P=0.001 
Z=3.218 
P=0.001 
Z=3.669 
P=0.000 
AIH 1 vs AIH 2 Z=0.975 
P=0.330 
Z=0.454 
P=0.650 
Z=1.565 
P=0.118 
Z=0.805 
P=0.421 
AIH 1 vs Hepatitis B Z=2.960 
P=0.003 
Z=2.615 
P= 0.009 
Z=3.166 
P=0.002 
Z=1.276 
P=0.202 
AIH 1 vs Hepatitis C Z=1.789 
P=0.074 
Z=0.833 
P=0.405 
Z=2.255 
P=0.024 
Z=0.793 
P=0.428 
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Table 9 : Serum immunoglobulins in various types of hepatitis and healthy contacts 
Groups Number 
of cases 
Serum IgG [mg/dl] 
Mean±SD 
Serum IgA [mg/dl] 
Mean±SD 
Serum IgM [mg/dl] 
Mean±SD 
Healthy Controls 18 1226.00±173.771 253.69±131.81 150.194±90.87 
AIH 1 59 2493.24±578.64 412.74±177.32 216.97±94.53 
AIH 2 6 1949.67±571.66 262.000±110.55 223.11±178.79 
AIH 3 1 3130.00 197.00 99.00 
Hepatitis B 8 1937.88±742.21 294.88±160.81 172.37±98.77 
Hepatitis C 8 1690.75±533.43 291.91±164.21 195.175±138.088 
Table 10: Showing statistical significance of immunoglobulins in various types of chronic hepatitis 
Groups Serum IgG [mg/dl] 
Mean±SD 
Serum IgA [mg/dl] 
Mean±SD 
Serum IgM [mg/dl] 
Mean ±SD 
Healthy Contacts vs AIH 1 Z=6.392 
P=0.000 
Z=3.491 
P=0.000 
Z=2.775 
P=0.006 
Controls vs AIH 2 Z=2.468 
P=0.014 
Z=0.267 
P=0.790 
Z=0.867 
P=0.386 
Controls vs Hepatitis B Z=2.112 
P=0.035 
Z==0.722 
P=0.470 
Z=0.667 
P=0.505 
Controls vs Hepatitis C Z=2.723 
P=0.006 
Z=0.500 
P=0.617 
Z=0.556 
P=0.578 
AIH 1 vs AIH 2 Z=1.825 
P=0.068 
Z=2.41 
P=0.041 
Z=0.453 
P=0.578 
AIH 1 vs Hepatitis B Z=1.779 
P=0.075 
Z=1.595 
P=0.111 
Z=1.073 
P=0.283 
AIH vs Hepatitis C Z=3.307 
P=0.001 
Z=1.934 
P=0.053 
Z=0.938 
P=0.348 
 
Table 9 and 10 shows in AIH 1 there was polyclonal 
hypergammaglobulinemia. All the serum IgG [P.000], 
IgA [P.000], IgM [P.006] were significantly increased 
in comparison to controls. In AIH 2 and chronic 
hepatitis B and C only serum IgG was significantly 
increased in comparison to controls. Only one case was 
SLA antibody positive and this case also showed raised 
IgG. Hepatitis B, Hepatitis C, did not show any 
significant difference in IgA, IgM. Serum IgA & IgM 
were raised significantly in AIH 1 as compared to 
controls. AIH 1 had significantly raise IgG as 
compared to Hepatitis C [Table 9 and 10] 
 
Discussion 
AIH is a chronic necroinflammatory disease of the 
liver characterized by hypergammaglobulinemia, 
interface hepatitis, characteristic autoantibodies and 
association with HLA antigens. 
In present study type 1 AIH was found to be more 
common [89.41%], followed by type 2 AIH [9.11%] 
and only one patient had type 3 AIH [1.5%]. Although 
now days anti SLA antibody positive cases are also 
kept in type 1 AIH. 
Like us other Indian studies have also found high 
prevalence of type 1 AIH which is 82% from Delhi 
[31], 71.2% from Mumbai [32] and 92% from 
Lucknow [33]. Western literature also found AIH 1 in 
80% of cases of total AIH [11]. 
Sex wise distribution in majority of studies done earlier 
showed female predominance which varies from 2.5 to 
6 times more as compared to males. [ Table 11] where 
as in our study males were slightly more affected than 
females with male to female ratio of 4:3 
Table 11 : Showing male to female ratio in AIH 
Group Region Year Male to female ratio 
Chowdhuriet al., [33] Lucknow, India 2005 1:4 
Gupta et al., [31] Delhi, India 2001 1:3 
Koay and Chine-Nanlin[34] Taiwan 2005 1:6 
Al-obeidyet al., [35] Baghdad 2009 1:2.5 
Present study Varanasi India 2017 4:3 
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Clinical features revealed that jaundice [71.2%], anorexia [86%], weight loss, weakness [93.3%], pallor [8.6%] were 
more common in present study.Clinical features are highly variable in different studies [Table 12] 
Table 12: Showing comparative clinical features of patients with autoimmune hepatitis 
Clinical features 
 
Amrapurkar et 
al., 2015 
n= 126 
Koay and 
Ching-Nanlin 
2005 
n=27 
Chaudhuri      
et al., 2005 
Lucknow 
n= 38 
Rajesh et al., 
2001 New 
Delhi 2001 
n= 39 
Present study 
n= 66 
No % No % No % No % No % 
Jaundice 75 59.5 14 57.9 21 55.2 32 83 4 71.2 
Nausea, vomiting, 
abdominal pain 
0 0 8 29.6 9 23.6 0 0 44 66.66 
Anorexia _ _ 11 40.7 _ _ 32 83 57 86.4 
Weight loss _ _ _ _ _ _ _ _ 51 77.2 
Weakness and 
Fatigue 
_ _ _ _ _ _ 32 83 62 93.3 
Pallor _ _ _ _ _ _ _ _ 57 86.3 
Diarrhoea 
[recurrent] 
_ _ _ _ _ _ _ _ 10 15.2 
Encephalopahy 7.0 5.55 1 37.7 9 23.6 6 15 8 12 
Ascitis and edema 
of feet 
41 32.53 6 22.2 13 34.2 17 43 38 57.6 
 
 
Autoantibody profile showed that anti smooth muscle 
antibody was the commonest antibody detected in our 
series in type 1 AIH [71.2%] 
Contrary to our study earlier western literature [40] 
reported ASMA in only 35% cases but some recent 
Western Literature like us [41, 42] also reported 
ASMA in 70-80% cases. One of the Indian Studies 
[33] also found ASMA in 60-65% cases. 
ANA was detected by indirect immunofluorescence as 
combined frozen section of rat, liver, kidney and 
stomach in only 16.6% cases but all samples were 
tested by ELISA method, then ANA was found to be 
positive in [30.3%] cases. 
More or less similar to our observation other workers 
from Minnesota and USA[24, 41] reported prevalence 
of ANA in only 13-15% cases by Immunofluorescent 
Test method which is very much closer to our 
observation. 
Contrary to our findings some other workers from 
India [32] reported prevalence of ANA positivity in 
65.6% and one study from Taiwan [34] reported ANA 
positivity in 96.5%. Difference between ELISA test 
and Immunofluorescent Test [IIF] for ANA is well 
reported. 
Many studies [43-45] have noticed that ANA positivity 
on rat liver kidney is low as compared to human 
epithelial line and ELISA ANA positivity is reported to 
be 12% in chronic viral hepatitis [46] but in our study 
none of the patients was positive . This could be due to 
small number of cases. 
Anti parietalcell antibody was positive in 27 % cases of 
AIH 1. APCA may be detected in 2.5 to 19.5% healthy 
controls [47, 48, 49]. APCA is marker of autoimmune 
gastritis and pernicious anaemia where it is detected in 
85-90% cases [50-51]. Besides this it is also detected in 
autoimmune thyroid diseases, type 1 diabetes mellitus, 
and vitiligo [51]. 
Two of our ANA positive patients [3.38%] of AIH 1 
had anti smith [anti Sm] antibodies and anti RNP 
antibodies. One patient was 36 years old male and 
other was 6 years old female. Both these patients 
presented with chronic recurrent jaundice, 
hepatosplenomegaly, anaemia and arthritis. This 
suggests that both patients had SLE. Like us other 
workers [52] also reported that 1 to 2.1 patient of AIH 
1 have associated SLE.  
Another 2 patients had anticentromere antibody, one 
was 18 years old female and another was 26 years old 
female. No classical feature of scleroderma and 
primary biliary cirrhosis was present but disease was of 
severe intensity. Anti centromere antibody was 
reported in 131 patients of AIH type 1 in Korea [53] 
Anti-mitochondrial antibody [AMA] have been 
reported in 8.20% patients of AIH[29] but in India 
Chowdhuriet al., [33] reported very low frequency of 
AMA which is very close to our observation because 
we found AMA in only 3.4% cases. Type 2 AIH 
formed only 9% cases where anti LKM antibody was 
detected. Males and females were equally affected and 
mostly patients were children. Its incidence is variable 
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.Most of the studies [10, 42, 54] reported it in low 
frequency [3 to 4 %]. Some of the studies from 
India[32]and Baghdad [35] reported its higher 
prevalence in 14% and 16.4% respectively. 
Anti SLA antibody is uncommon in our country. We 
found only one case of SLA antibody in female child. 
Contrary to our study several studies [2, 12, 55] 
reported very high prevalence of this antibody varying 
from 18.7% to 40%. Anti SLA antibody positivity is 
associated with more severe disease and poor 
outcome[12]. Serum SGOT, SGPT, total bilirubin, 
direct and indirect bilirubin, alkaline phosphatase were 
significantly elevated in AIH which is in accordance 
with other studies[33, 34]. Raised serum 
gammaglobulin is found in 73% patients of AIH [8]. 
Now it remains a cornerstone features of the diagnosis 
of AIH. It is due to increased number of plasma cells in 
bone marrow and liver. Mean value of Serum IgG was 
2493.24 ±578.649 mg/dl . Raised serum IgG was 
reported in patients of AIH with mean value of 1850 ± 
70 mg/dl by Koay and Chin [34]. Alobeidyet al., [33] 
studied 73 patients at AIH and found elevated IgG with 
mean of 2447±248 mg/dl but did not found elevated 
IgG in type 2 AIH. 
Thus our study concludes that ASMA and or Factin 
antibody is positive in all cases of AIH but ANA 
positivity in AIH is low in our country. Our study also 
includes that LC -1 antibody and anti SLA antibody are 
very rare in AIH in our country. Similarly anti LKM 
antibody and its related AIH 2 is less common. Study 
also shows that anti parietal cell Ab is frequently found 
in AIH 1 cases. 
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